News from sosei heptares A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 20, 2020, 04:05 ET Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel...


Nov 11, 2020, 02:55 ET Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020

Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine...


Nov 02, 2020, 07:46 ET Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases

Sosei Group Corporation ("the Company") (TSE: 4565) has entered into an agreement1 with Tempero Bio, under which Tempero Bio has in-licensed...


Sep 28, 2020, 03:25 ET Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials

Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new...


Sep 03, 2020, 04:57 ET Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy

Sosei Group Corporation ("the Company") (TSE: 4565) today announces the appointment of Hironoshin Nomura, as Senior Vice President Investor Relations ...


Aug 13, 2020, 03:52 ET Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...


Jul 16, 2020, 02:47 ET Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds

Sosei Group Corporation ("the Company") (TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen ...


Jun 05, 2020, 03:18 ET Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Sosei Group Corporation ("the Company") (TSE: 4565) notes that its strategic alliance partner Novartis has announced that full results from the Phase ...


May 13, 2020, 03:43 ET Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020

Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...


May 07, 2020, 04:00 ET Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia

Sosei Group Corporation ('the Company') (TSE: 4565) announces that it has made further significant progress with its orexin program, which is being...


May 01, 2020, 02:48 ET Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Sosei Group Corporation ("the Company"; TSE: 4565) notes that its strategic alliance partner Novartis (SWX: NOVN) announced that the European...


Apr 14, 2020, 04:00 ET Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program

Sosei Group Corporation ("the Company") (TSE: 4565) today announces it will apply its unique structure-based drug design platform and capabilities to ...


Mar 25, 2020, 05:00 ET Sosei Heptares Announces New Board Director Appointment and Executive Promotion

Sosei Group Corporation ("the Company"; TSE: 4565) today announces the appointment of Mr. Rolf Soderstrom as a new Board Director and the promotion...


Mar 20, 2020, 05:00 ET Sosei Heptares Announces New Publication Highlighting the Potential of Structure-based Approaches to Generate Novel Peptide-based Drugs Targeting GPCRs

Sosei Group Corporation ("the Company") (TSE: 4565) announces that a review article entitled 'Advances in Therapeutic Peptides Targeting G...


Feb 13, 2020, 02:14 ET Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months Ended 31 December 2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the twelve...


Jan 13, 2020, 19:05 ET Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Sosei Group Corporation ("the Company") (TSE: 4565) announces that significant scientific progress at its spin-off companies Orexia Limited...


Dec 24, 2019, 04:00 ET Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration

Sosei Group Corporation ("the Company"; TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has nominated a third clinical...


Dec 23, 2019, 03:00 ET Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer

Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has dosed the first subject in ...


Nov 28, 2019, 04:02 ET Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro® Breezhaler® (an inhaled once-daily fixed-dose combination of...


Nov 19, 2019, 03:00 ET Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives

Sosei Group Corporation ("the Company"; TSE: 4565) announces the formation of a new Scientific Advisory Board (SAB) to advise on the Company's...


Nov 12, 2019, 03:00 ET Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine...


Oct 09, 2019, 03:00 ET Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target

Sosei Group Corporation ("the Company"; TSE: 4565) announces that it has been notified by its partner Genentech, a member of the Roche Group, of its...


Oct 01, 2019, 03:00 ET Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

Sosei Group Corporation ("the Company"; TSE: 4565) notes that Novartis has announced positive results from its Phase III IRIDIUM trial. The results...


Sep 12, 2019, 04:00 ET Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum

Sosei Group Corporation ("the Company"; TSE: 4565) today held an Investor R&D Event in Tokyo, Japan, discussing how the integration of its...


Aug 13, 2019, 03:33 ET Sosei Heptares Operational Highlights and Consolidated Results for the First Half of FY2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...